Vaxcyte, Inc.
PCVX
주식 순위
#2112
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage,... Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
주가
$63.40
마지막 동기화: 2026-10-16
시가총액
$9.72B
변동 (1일)
-2.87%
변동 (1년)
49.56%
국가
US
거래 Vaxcyte, Inc. (PCVX)
카테고리
Healthcare
Vaxcyte, Inc. (PCVX)의 EPS
June 2026 기준 EPS TTM: $-7.64
Vaxcyte, Inc.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 $-7.64입니다. 2023년 말에는 회사의 EPS가 $-4.14였으며, 이는 2022년의 EPS $-3.44와 증가입니다.
Vaxcyte, Inc.의 EPS 기록 (2017 ~ 2026)
매년 말의 EPS
| 연도 | EPS | 변화 |
|---|---|---|
| 2026 (TTM) | $-7.64 | 101.05% |
| 2024 | $-3.80 | -8.21% |
| 2023 | $-4.14 | 20.35% |
| 2022 | $-3.44 | 78.24% |
| 2021 | $-1.93 | -35.02% |
| 2020 | $-2.97 | -78.94% |
| 2019 | $-14.10 | 73.65% |
| 2018 | $-8.12 | 67.77% |
| 2017 | $-4.84 | 0.00% |
유사 기업 또는 경쟁사의 EPS
| 회사 | EPS | EPS 차이 | 국가 |
|---|---|---|---|
| $17.32 | -326.70% |
US
|
|
| $-7.98 | 4.45% |
US
|
|
| $-5.29 | -30.76% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -463.09% |
NL
|
